EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Xenon Pharmaceuticals's enterprise value is $2,578.51 Mil.
Xenon Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Xenon Pharmaceuticals's EV-to-Revenue for today is .
The historical rank and industry rank for Xenon Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Xenon Pharmaceuticals was 20966.59. The lowest was 2.33. And the median was 51.59.
XENE's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.07 * Ranked among companies with meaningful EV-to-Revenue only.
Xenon Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for Xenon Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xenon Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Xenon Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenon Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Xenon Pharmaceuticals's EV-to-Revenue falls into.
Xenon Pharmaceuticals's current Enterprise Value is $2,578.51 Mil.
Xenon Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenon Pharmaceuticals's share price for today is $42.99.
Xenon Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenon Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Xenon Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XENE has been successfully added to your 